文献速递免疫规划传染病防控与疫情报告

疫苗诱导与突破感染诱导的SARS-CoV-2宿主反应蛋白质组学特征

Proteomic signatures of vaccine-induced and breakthrough infection-induced host responses to SARS-CoV-2.
PubMed 文献 · Vaccine · 2024-11-08

本研究评估有(CoV-P)或无(CoV-N)SARS-CoV-2感染史个体在初种疫苗后及突破感染(CoV-BT)后的差异蛋白表达。初种疫苗个体依赖先天免疫机制,包括补体和凝血级联及自然杀伤细胞介导的细胞毒性;突破感染免疫机制则依赖T细胞介导免疫。这些机制差异可能有助于解释疫苗诱导与突破感染相关结局的异质性。

要点

  • 初种疫苗个体依赖补体和凝血级联及自然杀伤细胞介导的细胞毒性等先天免疫机制。
  • 突破感染免疫机制依赖T细胞介导的免疫。
  • 机制差异可能有助于解释疫苗诱导与突破感染相关结局的异质性。

核心结论

  • 初种疫苗个体依赖先天免疫机制,突破感染免疫机制依赖T细胞介导免疫,这些机制差异可能有助于解释疫苗诱导与突破感染相关结局的异质性。

研究设计与样本

  • 评估有(CoV-P)或无(CoV-N)既往SARS-CoV-2感染史个体在初种疫苗后及突破感染(CoV-BT)后的差异蛋白表达。

主要发现

  • 初种疫苗个体依赖先天免疫机制,包括补体和凝血级联及自然杀伤细胞介导的细胞毒性。
  • 突破感染免疫机制依赖T细胞介导的免疫。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The severity of SARS-CoV-2 illness is influenced by factors including age, sex, pre-existing health conditions, and individual immune responses. However, the mechanisms conferring immunity following antigenic challenge have not been fully elucidated. There are currently no studies evaluating longitudinal proteomic changes in individuals following vaccination and breakthrough, limiting our understanding of the underlying mechanisms driving conferred immunity. In this work, we evaluated the differential protein expression in individuals with (CoV-P) or without (CoV-N) prior SARS-CoV-2 infection following primary vaccination and after breakthrough infection (CoV-BT). Overall, we found that individuals receiving primary vaccination relied on innate immune mechanisms, including complement and coagulation cascades, and natural killer cell-mediated cytotoxicity, while conversely, breakthrough infection immune mechanisms relied on T cell-mediated immunity. These mechanistic differences may help explain heterogeneity associated with vaccine-induced and breakthrough infection-related outcomes.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Williams E, Echeverri Tribin F, Carreño JM, et al. Proteomic signatures of vaccine-induced and breakthrough infection-induced host responses to SARS-CoV-2. Vaccine. 2024. PMID: 39520894. doi:10.1016/j.vaccine.2024.126484

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。